Prognostic markers other than hormone receptors in breast cancer

Journal of Clinical Ligand Assay

Volumn 21, Issue 1, 1998, Pages 41-46

  Fleisher, Martin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer markers; C erb B 2; Cathepesin D; Metastatic markers; Prognostic factors; Proteases and inhibitors

Indexed keywords

CATHEPSIN D; HORMONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SCREENING; HUMAN; HUMAN CELL; MOLECULAR GENETICS; MONITORING; ONCOGENE; ONCOGENE C ERB; PROGNOSIS;

EID: 0031925511     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Thor AD, Schwartz LH, Koerner FC, et al: Analysis of c-erb B-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989;49:7147.
2. Clark GM, McGuire WL: Follow-up study of Her-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944.
3. Winstanley J, Cooke T, Murray GD, et al: The long-term prognostic significance of c-erb b-2 in primary breast cancer. Br J Cancer 1991;63:447.
4. Ciocca DR, Fujimura FK, Tandon AK, et al: Correlation of HER-2/Neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992;84:1279.
5. Foekens JA, Schmitt M, van Putten WLJ, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648.
6. Kim SJ, Shiba E, Kobayashi T, et al: Prognostic Impact of Urokinase-type plasminogen activator (PA). PA inhibitor type-1 and tissue type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998;4:177.
7. Janicke F, Schmitt M, Hafter R, et al: Urokinase-type Plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinalysis 1990;4:69.
8. Faekens JA, Schmitt M, van Putten WLJ, et al: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101.
9. Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297.
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177.
11. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb B-related gene in a human mammary carcinoma. Science 1985;229:974.
12. Coussens L, Tang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132.
13. Fukushige SI, Matsubara KI, Yoshida M, et al: Localization of a novel v-erb B-related gene, c-erb B-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955.
14. Dougall WC, Qian X, Peterson MJ, et al: The neu oncogene: signal trarisduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109.
15. Iwase H, Itoh Y, Kuzushima T, et al: Simultaneous quantitative analyses of c-erb B-2 protein, epidermal growth factor receptor, Cathepsin D, and hormone receptors in breast cancer. Cancer Detection and Prevention 1997;21:29.
16. Kallioniemi OP, Holli K, Visakorpi, et al: Association of c-erb B-2 protein over- expression with high rate of cell proliferation, increased risk of visceral metastases and poor long-term survival in breast cancer. Int J Cancer 1991;49:650.
17. Allred DC, Clark. GM, Tendon AK, et al: Her-2/neu in node-negative breast cancer: prognostic significance of over expression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599.
18. Tetu B, Brisson J: Prognostic significance of Her-neu oncoprotein expression in node-positive breast cancer. Cancer 1994;73:2359.
19. Ali IU, Campbell G, Lidereau R, et al: Amplification of c-erb b-2 and aggressive human breast tumors. Science 1988;240:1795.
20. Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989;4:1153.
21. Wu JT, Astill ME, Zhang P: Detection of the extracellular domain of c-erb B-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 1993;7:31.
22. Gusterson BA, Machin LG, Gullick WJ, et al: Immunohistochemical distribution of c-erb B-2 in infiltrating and in situ breast cancer. Int J Cancer 1988;42:842.
23. Lodato RF, Maguire HC, Greene MJ, et al: Immunohistochemical evaluation of c-erb B-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Med Pathol 1990;3:449.
24. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erb B-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988;48:1238.
25. Tandon AK, Clark GM, Chamness GC, et al: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120.
26. Barnes DM, Lammie GA, Millis RR, et al: An immunohistochemical evaluation of c-erb B-2 expression in human breast carcinoma. Br J Cancer 1988;58:448.
27. Gusterson BA, Machin LG, Gullick WJ, et al: C-erb B2 expression in benign and malignant breast disease. Br J Cancer 198;58:453.
28. Wright C, Angus B, Nicholson S, et al: Expression of c-erb B-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 1989;49:2087.
29. Borg A, Tandon AK, Sigurdsson H, et al: Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332.
30. Lacroix H, Inglehart JD, Skinner MA, et al: Over expression of erb B-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989;4:145.
31. Elledge RM, Green S, Ciocca D, et al: Her-2 expression and response to tamoxifin in estrogen receptor positive breast cancer; A Southwest Oncology Group study. Clin Cancer Res 1998;4:7.
32. Schmitt M, Janicke F, Graeff H: Tumor-associated fibrinolysis: The prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagulation and Fibrinolysis 1990;1:695.
33. Duffy, MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145.
34. Bouchet C, Spyratos F, Martin PM, et al: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398.
35. Janicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Research and Treat 1993;24:195.
36. Westley BR, Rochefort H: A secreted glycoprotein induced by oestrogen in human breast cancer cell lines. Cell 1980; 20:353.
37. Yonezawa S, Takahashi T, Wang XJ, et al: Structures at the proteolytic processing region of Cathepsin D. J Biol Chem 1988;263:16504.
38. Maudelonde T, Khalaf S, Garcia M, et al: Immunoenzymatic assay of 52 kdal Cathepsin D in 182 breast cancer cytosols. Low correlation with other prognostic parameters. Cancer Res 1988;48:462.
39. Spyratos F, Brouillet JP, Defrenne A, et al: Cathepsin D an independent prognostic factor for metastasis of breast cancer. Lancet 1989;ii:1113.
40. Walker RA, Denley H, Dookeran KA: Cathepsin D in breast carcinomas - the role of the stromal cell component. Oncology Rep 1994;1:227.
41. Freiss G, Vignon F, Pau B, et al: A two site immunoenzymetric assay of 52 Kdal pro-cathepsin D, and its use in human breast diseases. Clin Chem 1989;35:234.
42. Shay JW: Aging and Cancer: Are telomeres and telomerase the connection? Mol Med Today 1995;1:378.
43. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 1995;266:2011.
44. Carey LA, Hedican CA, Henderson GS, et al: Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancer. Clin Cancer Res 1998;4:435.
45. Clark GM, Allied DC, Hilsenbeck SG, et al: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 1997;57:5505.
46. Treatment of early stage breast cancer (Consensus Conference). JAMA 1991;265:391.